Introduction
Detrusor hyperreflexia is a particular form of bladder instability frequently found in patients with high spinal cord lesions and characterised by an impairment of voluntary command of micturition, impairment or loss of bladder sensations, detrusor contraction on external mechanical stimulation and sometimes unco-ordinated micturition due to detrusor-sphincter dyssynergia [1] . Current treatment methods for detrusor hyperreflexia include bladder training, intermittent catheterisation, augmentation cystoplasty and the use of anticholinergic drugs. However, none of these treatments is completely successful and in many cases have unwanted side effects [2] .
Cromakalim acts as a potassium channel opener in smooth muscle mediating relaxation in a number of smooth muscles including vascular smooth muscle [3] and the detrusor muscle of the bladder [4] [5] [6] [7] . Cromakalim abolishes spontaneous bladder contractions in pigs [5] , rats [8] and rabbits [9] with bladder instability, with little change in other urodynamic variables. Cromakalim also lowers blood pressure in pigs when administered in doses that suppress the unstable contractions [5] .
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Methods
Six males aged 24-41 years (71 ± 7 kg) with high spinal cord injury at or above T1O and with established reflex micturition entered this study. All the patients had normal biochemistry, haematology, blood pressure, ECG and urinalysis results and were normal on physical examination except for symptoms resulting from the spinal lesion. The purpose of the study was explained to all patients and written informed consent was obtained. The protocol was approved by the Austin Hospital Ethics Committee.
The urodynamic procedure has been described previously [11] period prior to drug infusion, the final 5 min of the infusion and a 10 min period after drug infusion. The blood pressure changes accompanying bladder contractions were not included. All patients except for one were hospitalised overnight for observation.
Results
The levcromakalim infusion did not alter the infused volume which precipitated detrusor contraction, the interval between contractions or voidings nor did it significantly alter the volume voided, or the resting and maximal bladder pressure (Table 1 ). There was, however, an increase in the duration of contraction by 36% following levcromakalim infusion (Table 1) .
Levcromakalim produced a rapid fall in supine blood pressure from a pre-infusion level of 126 + 13/67 ± 9 mm Hg to 104 ± 25/52 ± 12 mm Hg (P < 0.05 systolic, P < 0.001 diastolic) during the second half of the infusion. In the period immediately after the infusion blood pressure returned to 118 ± 24/63 + 11 mm Hg. Heart rate increased from 59 ± 15 beats min-' to 76 ± 17 bpm (P < 0.05) during infusion and remained above baseline after infusion (68 ± 16, P < 0.05).
In all patients the start of each bladder contraction was usually accompanied by a few seconds of hyperreflexia indicated by an increase in blood pressure. In five patients this was asymptomatic but one patient experienced flushing associated with the hyperreflexia. In one patient the fall in blood pressure was dramatic (from baseline 112/55 to 72/40 mm Hg). This fall persisted after the end of the study but recovered to baseline in the next 5 h. No other adverse events were observed either during the study or during the following 24 h. 
Discussion
In in vitro studies cromakalim has been shown to inhibit spontaneous and exogenously induced contractile activity of hyperreflexic human detrusor muscle [5, 7] . Nurse et al. [7] have further referred to an unpublished study that reported a clinical benefit of an unknown dose of levcromakalim in some patients with detrusor instability or hyperreflexia.
In our study, levcromakalim 7.5 ±g kg-' i.v. failed to alter urodynamic parameters associated with the hyperreflexic response in any clinically meaningful way. Higher doses may be more effective but are likely to be accompanied by falls in blood pressure.
Intravesical instillation of oxybutynin chloride is an effective treatment of detrusor hyperreflexia that minimises systemic side effects [12, 13] . As intravesically administered cromakalim inhibited spontaneous activity in the rabbit urinary bladder in a rabbit hyperreflexic model without any change in blood pressure [9] , studies with intravesical administration of levcromakalim in man may demonstrate a clinical benefit without adverse side effects.
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